Cell MedX Corp. - FORM 10-Q - EX-32.2 - CERTIFICATION - January 14, 2016

Attached files

file filename
10-Q - 10-Q - Cell MedX Corp.form10q.htm
EX-31.1 - CERTIFICATION - Cell MedX Corp.ex311.htm
EX-31.1 - CERTIFICATION - Cell MedX Corp.ex321.htm
EX-10.30 - LOAN AGREEMENT AND NOTE PAYABLE DATED DECEMBER 23, 2015, AMONG CELL MEDX CORP., AND COVENTRY CAPITAL LLC. - Cell MedX Corp.ex1030.htm
EX-31.2 - CERTIFICATION - Cell MedX Corp.ex312.htm
EX-10.29 - NON-BINDING LETTER OF INTENT DATED DECEMBER 4, 2015 TO ENTER INTO DEVELOPMENT AGREEMENT AND LICENSE AGREEMENT AMONG CELL MEDX CORP., CLAUDIO TASSI, AND BIOFORMED AESTHETIC S.L. - Cell MedX Corp.ex1029.htm
 
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
 
 
In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending November 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
 
 
 (1)   The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 
(2)   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Dated: January 14, 2016
 
 
/s/ Yanika Silina
Yanika Silina
Chief Financial Officer
(Principal Accounting Officer)

 
 
 

Cell MedX Corp. Reports